| Residential College | false |
| Patent Number | US9840526B1 |
| Status | 已授權 Granted |
| Iridium (III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent | |
| 2017-12-12 | |
| Application Date | 2017-07-27 |
Chung-Hang LEUNG1  ; Hai-Jing ZHONG1; Dik-Lung MA2 ; Hui-Min WANG3
| |
| Country | China |
| Subtype | 发明专利Invention |
| Abstract | Bromodomain - containing protein 4 (BRI ) ) has recently emerged as an attractive epigenetic target for anticancer therapy . Iridium (III ) complexes are useful as irreversible inhibitor of BRD4. |
| Keyword | Brd4 Inhibitor |
| Document Type | Patent |
| Collection | Institute of Chinese Medical Sciences |
| Corresponding Author | Dik-Lung MA |
| Affiliation | 1.UM 2.HKBU 3.Kaohsiung Medical University |
| Recommended Citation GB/T 7714 | Chung-Hang LEUNG,Hai-Jing ZHONG,Dik-Lung MA,et al. Iridium (III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent. US9840526B1[P]. 2017-12-12. |
| APA | Chung-Hang LEUNG., Hai-Jing ZHONG., Dik-Lung MA., & Hui-Min WANG (2017-07-27). Iridium (III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment